Shares of Evotec AG (NASDAQ:EVO – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $3.00, but opened at $2.67. Evotec shares last traded at $2.6730, with a volume of 83,166 shares.
Wall Street Analyst Weigh In
A number of research firms have commented on EVO. Berenberg Bank began coverage on shares of Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright initiated coverage on shares of Evotec in a report on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $7.00.
View Our Latest Stock Report on EVO
Evotec Price Performance
Evotec (NASDAQ:EVO – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. The company had revenue of $297.02 million during the quarter. As a group, equities research analysts forecast that Evotec AG will post -0.63 EPS for the current year.
Institutional Investors Weigh In On Evotec
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Evotec by 25.7% during the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after buying an additional 367,545 shares during the last quarter. DCF Advisers LLC raised its holdings in Evotec by 7.6% during the 3rd quarter. DCF Advisers LLC now owns 1,198,993 shares of the company’s stock valued at $4,352,000 after buying an additional 84,500 shares during the last quarter. WCM Investment Management LLC raised its holdings in Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after buying an additional 67,917 shares during the last quarter. ABC Arbitrage SA raised its holdings in Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after buying an additional 422,230 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Evotec during the 4th quarter valued at $565,000. 5.81% of the stock is currently owned by institutional investors.
About Evotec
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Read More
- Five stocks we like better than Evotec
- Qualcomm Stock Doubles: New Era? Or Another False Start?
- 3 Industrial Stocks That Just Crushed Earnings
- A Quantum Shift: Why Speculative Money Is Ditching AI
- Reading the Stripes: Is The Industrial Recession Over?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
